HK1170936A1 - Macrocyclic hepatitis c serine protease inhibitors - Google Patents

Macrocyclic hepatitis c serine protease inhibitors

Info

Publication number
HK1170936A1
HK1170936A1 HK12111721.9A HK12111721A HK1170936A1 HK 1170936 A1 HK1170936 A1 HK 1170936A1 HK 12111721 A HK12111721 A HK 12111721A HK 1170936 A1 HK1170936 A1 HK 1170936A1
Authority
HK
Hong Kong
Prior art keywords
protease inhibitors
serine protease
macrocyclic hepatitis
macrocyclic
hepatitis
Prior art date
Application number
HK12111721.9A
Other languages
English (en)
Chinese (zh)
Inventor
Yiyin Ku
Yat Sun Or
Sable H Wagaw
Ken Engstrom
Tim Grieme
Ahmad Sheikh
Jianzhang Mei
Keith F Mcdaniel
Hui-Ju Chen
Jason P Shanley
Dale J Kempf
David J Grampovnik
Ying Sun
Dong Liu
Yonghua Gai
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42005677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1170936(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of HK1170936A1 publication Critical patent/HK1170936A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK12111721.9A 2008-09-11 2012-01-06 Macrocyclic hepatitis c serine protease inhibitors HK1170936A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19172508P 2008-09-11 2008-09-11
US20968909P 2009-03-10 2009-03-10

Publications (1)

Publication Number Publication Date
HK1170936A1 true HK1170936A1 (en) 2013-03-15

Family

ID=42005677

Family Applications (4)

Application Number Title Priority Date Filing Date
HK12100145.0A HK1159515A1 (en) 2008-09-11 2012-01-06 Macrocyclic hepatitis c serine protease inhibitors
HK12111722.8A HK1171184A1 (en) 2008-09-11 2012-01-06 Macrocyclic hepatitis c serine protease inhibitors
HK12111721.9A HK1170936A1 (en) 2008-09-11 2012-01-06 Macrocyclic hepatitis c serine protease inhibitors
HK12111723.7A HK1170937A1 (zh) 2008-09-11 2012-01-06 大環化合物的丙型肝炎絲氨酸蛋白酶抑制劑

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK12100145.0A HK1159515A1 (en) 2008-09-11 2012-01-06 Macrocyclic hepatitis c serine protease inhibitors
HK12111722.8A HK1171184A1 (en) 2008-09-11 2012-01-06 Macrocyclic hepatitis c serine protease inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12111723.7A HK1170937A1 (zh) 2008-09-11 2012-01-06 大環化合物的丙型肝炎絲氨酸蛋白酶抑制劑

Country Status (41)

Country Link
US (3) US8420596B2 (ja)
EP (5) EP2340029B1 (ja)
JP (4) JP5259537B2 (ja)
KR (3) KR101379365B1 (ja)
CN (3) CN103896950A (ja)
AR (3) AR073568A1 (ja)
AU (1) AU2009292182B2 (ja)
BR (2) BRPI0918724B8 (ja)
CA (1) CA2736895C (ja)
CL (2) CL2011000512A1 (ja)
CO (1) CO6341565A2 (ja)
CR (1) CR20140180A (ja)
CY (6) CY1115137T1 (ja)
DK (5) DK2468286T3 (ja)
DO (1) DOP2011000077A (ja)
EA (2) EA020580B1 (ja)
EC (2) ECSP11010879A (ja)
ES (5) ES2475163T3 (ja)
GT (2) GT201100056AA (ja)
HK (4) HK1159515A1 (ja)
HR (5) HRP20140494T1 (ja)
HU (2) HUE039478T2 (ja)
IL (2) IL218441A (ja)
LT (2) LT2805726T (ja)
LU (1) LU92667I2 (ja)
MX (1) MX2011002486A (ja)
MY (1) MY159820A (ja)
NL (1) NL300730I2 (ja)
NO (1) NO2015014I1 (ja)
NZ (2) NZ605550A (ja)
PA (1) PA8842201A1 (ja)
PE (3) PE20121312A1 (ja)
PL (5) PL2340029T3 (ja)
PT (5) PT2340029E (ja)
SG (1) SG179414A1 (ja)
SI (5) SI2805726T1 (ja)
TR (1) TR201809771T4 (ja)
TW (3) TWI450723B (ja)
UY (3) UY32099A (ja)
WO (1) WO2010030359A2 (ja)
ZA (2) ZA201101558B (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EP2483290A4 (en) * 2009-09-28 2013-05-01 Intermune Inc CYCLIC PEPTIC INHIBITORS FOR REPLICATION OF HEPATITIS C VIRUS
KR20120107529A (ko) 2010-01-25 2012-10-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110312973A1 (en) * 2010-03-10 2011-12-22 Bernd Liepold Solid compositions
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
AU2011352145A1 (en) * 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US9044480B1 (en) * 2011-03-03 2015-06-02 Abbvie Inc. Compositions and methods for treating HCV
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US20130072528A1 (en) * 2011-09-16 2013-03-21 Abbvie Inc. Methods for Treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2506085A (en) * 2011-10-21 2014-03-19 Abbvie Inc Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
DE112012003510T5 (de) * 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CN107964006A (zh) * 2012-01-11 2018-04-27 艾伯维公司 用于制备hcv蛋白酶抑制剂的方法
WO2014004674A2 (en) 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US9469673B2 (en) 2012-07-12 2016-10-18 Abbvie Inc. Crystaline forms of HCV inhibitor
TW201408669A (zh) 2012-08-08 2014-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9434738B2 (en) * 2013-01-10 2016-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
WO2015002952A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
US10149859B2 (en) 2013-09-11 2018-12-11 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20150175612A1 (en) * 2013-12-04 2015-06-25 Abbvie Inc. Crystal forms
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20150209403A1 (en) 2014-01-28 2015-07-30 Abbvie Inc. Dose Adjustment
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
US10113152B1 (en) 2014-10-03 2018-10-30 Abbvie Inc. Variant polypeptides capable of aminating aliphatic alpha keto acids
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
CR20170191A (es) * 2014-11-10 2017-09-29 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas de acción prolongada para la hepatitis c
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
HUE060259T2 (hu) 2015-07-22 2023-02-28 Enanta Pharm Inc Benzodiazepin származékok mint RSV-gátlók
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CA3052039A1 (en) 2017-02-01 2018-08-09 Abbvie Inc. Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and (±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid
CN107383021A (zh) * 2017-08-01 2017-11-24 安徽拜善晟制药有限公司 一种原料药帕利普韦的制备方法
KR20210138684A (ko) 2019-03-18 2021-11-19 이난타 파마슈티칼스, 인코포레이티드 Rsv 억제제로서의 벤조디아제핀 유도체
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
CN111378007B (zh) * 2020-05-08 2022-04-12 杭州濡湜生物科技有限公司 一种采用第二代Hoveyda-Grubbs催化剂制备帕利普韦的方法
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US11922331B2 (en) 2020-08-26 2024-03-05 Northrop Grumman Systems Corporation Machine-learning-based predictive ice detection
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
BR112023016970A2 (pt) 2021-02-26 2023-10-10 Enanta Pharm Inc Compostos heterocíclicos antivirais

Family Cites Families (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5861297A (en) 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
DE69934104T2 (de) 1998-03-31 2007-06-28 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von hepatitis c virus ns3 protease
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
JP2003526634A (ja) 1999-12-03 2003-09-09 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ｃ型肝炎ウイルスＮＳ３プロテアーゼのα−ケトアミド阻害剤
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CA2429359A1 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
FR2821272B1 (fr) 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
WO2003025563A1 (en) 2001-09-16 2003-03-27 Chemometec A/S Method and a system for detecting and optionally isolating a rare event particle
EP1429759A4 (en) 2001-09-26 2004-12-15 Bristol Myers Squibb Co COMPOUNDS FOR TREATING HEPATITIS C VIRUS
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US6869964B2 (en) 2002-05-20 2005-03-22 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis C virus inhibitors
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
US20030232386A1 (en) 2002-06-17 2003-12-18 Shah Dinesh O. Assay conjugate and uses thereof
AU2003243657A1 (en) 2002-06-26 2004-01-19 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CA2515216A1 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
CA2520886A1 (en) 2003-04-02 2004-11-04 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
WO2004089974A1 (en) 2003-04-10 2004-10-21 Boehringer Ingelheim International Gmbh Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
JP4231524B2 (ja) 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
WO2004094452A2 (en) 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CN1788006A (zh) * 2003-04-18 2006-06-14 安南塔制药公司 喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂
ATE378334T1 (de) 2003-05-21 2007-11-15 Boehringer Ingelheim Int Verbindungen als hepatitis c inhibitoren
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
JP4704342B2 (ja) 2003-09-22 2011-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
DE602004031298D1 (de) 2003-09-26 2011-03-17 Schering Corp Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902216A (zh) 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
FR2863268B1 (fr) 2003-12-09 2006-02-24 Sod Conseils Rech Applic Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
PE20050940A1 (es) 2003-12-11 2005-11-08 Schering Corp Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
WO2005075502A1 (en) 2004-01-28 2005-08-18 Boehringer Ingelheim International Gmbh Method of removing transition metals from reaction solutions comprising transition metal byproducts
AR047793A1 (es) 2004-01-30 2006-02-22 Medivir Ab Inhibidores de la serina proteasa ns-3 del vhc
US20050209135A1 (en) 2004-03-15 2005-09-22 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
AP2006003763A0 (en) 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
WO2005116054A1 (en) 2004-05-25 2005-12-08 Boehringer Ingelheim International, Gmbh Process for preparing acyclic hcv protease inhibitors
WO2006000085A1 (en) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
DE102004033312A1 (de) 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006033878A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic hcv protease inhibitors
EP1794179A1 (en) 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
CA2578356C (en) 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
WO2007001406A2 (en) * 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US20090036708A1 (en) 2004-10-14 2009-02-05 Lanqi Jia Novel Process for the Preparation of Nonracemic Long Chain alpha-Amino Acid Derivatives
JP2008517896A (ja) 2004-10-21 2008-05-29 ファイザー・インク Ｃ型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2332963A3 (en) 2005-03-08 2011-11-16 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
EP1876899A2 (de) 2005-04-25 2008-01-16 Basf Aktiengesellschaft Verwendung von 5-alkyl-6-phenylalkyl-7-amino-azolopyrimidinen, neue azolopyrimidine, verfahren zu ihrer herstellung und sie enthaltende mittel
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006128455A2 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20060276404A1 (en) 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
CA2611155A1 (en) 2005-06-02 2006-12-07 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
CA2611145A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US20060276406A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
WO2006130553A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
CN102643175B (zh) 2005-07-04 2014-12-10 赞南科技(上海)有限公司 钌络合物配体、钌络合物、固载钌络合物催化剂及其制备方法和用途
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
EP1910378B1 (en) 2005-07-20 2012-06-20 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
CN102816170A (zh) 2005-07-25 2012-12-12 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
ES2359939T3 (es) 2005-07-29 2011-05-30 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AR054882A1 (es) 2005-07-29 2007-07-25 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
SI1912997T1 (sl) 2005-07-29 2012-02-29 Tibotec Pharm Ltd Makrociklični inhibitorji virusa hepatitis C
AU2006275605B2 (en) 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
PL1934243T3 (pl) 2005-09-09 2011-10-31 Boehringer Ingelheim Int Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006301966A1 (en) 2005-10-11 2007-04-19 Array Biopharma, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US20070287664A1 (en) 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
WO2007130592A2 (en) 2006-05-04 2007-11-15 Crawford Ted C Head cap for a wrench head, wrench and method utilizing the same
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
DK2041156T3 (en) 2006-07-13 2014-02-24 Achillion Pharmaceuticals Inc 4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035271A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008019303A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008019289A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
WO2008021960A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis c serine protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US7687459B2 (en) 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20100189772A1 (en) 2006-09-27 2010-07-29 Coley Pharmaceutical Group, Inc Compositions of TLR ligands and antivirals
DK2084182T3 (da) 2006-10-03 2013-11-04 Cadila Healthcare Ltd Antidiabetiske forbindelser
US20120220520A1 (en) 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5345941B2 (ja) 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
EP2083844B1 (en) * 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CA2667031C (en) 2006-10-27 2013-01-22 Merck & Co., Inc. Hcv ns3 protease inhibitors
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2008057995A2 (en) 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008059046A1 (en) 2006-11-17 2008-05-22 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
US20100120716A1 (en) 2006-12-06 2010-05-13 Phenomix Corporation Macrocyclic hepatitis c serine protease inhibitors and uses therefor
AU2008205116A1 (en) 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis C protease inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2008092954A2 (en) 2007-02-01 2008-08-07 Tibotec Pharmaceuticals Ltd. Polymorphic forms of a macrocyclic inhibitor of hcv
WO2008095058A1 (en) 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Hcv protease inhibitors
AU2008212758B2 (en) 2007-02-08 2014-01-30 Medivir Ab Pyrimidine substituted macrocyclic HCV inhibitors
BRPI0807482A2 (pt) 2007-02-08 2014-05-13 Tibotec Pharm Ltd Fenilcarbamatos macrocíclicos inibidores de hcv
US20100087382A1 (en) 2007-02-16 2010-04-08 Boehringer Ingelheim International Gmbh Inhibitors of Hepatitis C NS3 Protease
CA2677843A1 (en) 2007-02-20 2008-08-28 Novartis Ag Macrocyclic compounds as hcv ns3 protease inhibitors
EP2125113A2 (en) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
WO2008114006A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
WO2008124384A2 (en) 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
CA2684086C (en) 2007-04-24 2014-05-27 F. Hoffmann-La Roche Ag Process for hcv protease inhibitor intermediate
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
KR20100024920A (ko) 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
TW200918524A (en) 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
WO2009010804A1 (en) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2009053828A2 (en) 2007-10-22 2009-04-30 Enanta Pharmaceuticals, Inc. P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
WO2009055335A2 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
JP5416710B2 (ja) 2007-11-20 2014-02-12 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
CA2708042A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
WO2009073713A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
US8193346B2 (en) 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
NZ586232A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
EP2225249B1 (en) 2007-12-21 2016-08-03 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
AU2009249443A1 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2285822A1 (en) 2008-05-09 2011-02-23 Boehringer Ingelheim International GmbH A method for preparing macrocycles
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
CN103536906A (zh) 2008-06-05 2014-01-29 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎
TW201012814A (en) 2008-07-01 2010-04-01 Centocor Ortho Biotech Products L P Cyclopropyl polymerase inhibitors
BRPI0916609A2 (pt) 2008-08-07 2015-08-04 Hoffmann La Roche Processo para a preparação de um macrociclo
US8765667B2 (en) 2008-08-20 2014-07-01 Michael Eissenstat HCV protease inhibitors
JP2012501654A (ja) 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
ES2474992T3 (es) 2008-09-16 2014-07-10 Boehringer Ingelheim International Gmbh Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de HCV
MX2011002602A (es) 2008-09-17 2011-04-07 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina.
US8603737B2 (en) 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
WO2010034105A1 (en) 2008-09-23 2010-04-01 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI480272B (zh) 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
EP2364159A4 (en) 2008-10-23 2012-06-13 Concert Pharmaceuticals Inc DETERIORIC MACROCYCLIC INHIBITORS OF NS3 VIRAL PROTEASE
US8296141B2 (en) * 2008-11-19 2012-10-23 At&T Intellectual Property I, L.P. System and method for discriminative pronunciation modeling for voice search
CA2743912A1 (en) 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
EA022272B1 (ru) 2008-11-21 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция эффективного ингибитора всг для перорального введения
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102300871A (zh) 2008-12-19 2011-12-28 吉里德科学公司 Hcv ns3蛋白酶抑制剂
JP2012516351A (ja) 2009-01-30 2012-07-19 アナコール ファーマシューティカルズ，インコーポレーテッド 化合物
US8642544B2 (en) 2009-04-01 2014-02-04 Amylin Pharmaceuticals, Llc N-terminus conformationally constrained GLP-1 receptor agonist compounds
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
EA022212B1 (ru) 2009-04-24 2015-11-30 Кадила Хелзкэр Лимитед Короткоцепочечные пептиды в качестве агониста рецептора паратиреоидного гормона (pth)
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
WO2010135748A1 (en) 2009-05-22 2010-11-25 Sequoia Pharmaceuticals Inc. Bimacrocyclic hcv ns3 protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011009961A1 (en) 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
ES2588204T3 (es) 2009-09-15 2016-10-31 Taigen Biotechnology Co., Ltd. Inhibidores de la proteasa de HCV
WO2011063502A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2011063501A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US20110178107A1 (en) 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors

Also Published As

Publication number Publication date
AR093924A2 (es) 2015-06-24
BRPI0918724A8 (pt) 2017-10-03
CN102641271A (zh) 2012-08-22
ES2525922T3 (es) 2015-01-02
CR20140180A (es) 2014-06-03
CN102641271B (zh) 2013-12-25
AU2009292182A1 (en) 2010-03-18
BRPI0918724B1 (pt) 2019-12-03
ECSP12011947A (es) 2012-07-31
US20100144608A1 (en) 2010-06-10
HRP20140494T1 (hr) 2014-07-04
EA201200390A1 (ru) 2012-12-28
US9309279B2 (en) 2016-04-12
EA020580B1 (ru) 2014-12-30
NL300730I1 (ja) 2016-01-07
ES2475815T3 (es) 2014-07-11
BR122012005261A2 (pt) 2015-07-14
ZA201101558B (en) 2018-11-28
SG179414A1 (en) 2012-04-27
TWI450723B (zh) 2014-09-01
HRP20141169T1 (hr) 2015-02-13
HUS1500020I1 (hu) 2018-12-28
CA2736895A1 (en) 2010-03-18
GT201100056AA (es) 2014-09-26
AR073568A1 (es) 2010-11-17
HK1171184A1 (en) 2013-03-22
IL218441A0 (en) 2012-04-30
ECSP11010879A (es) 2011-04-29
JP2010065035A (ja) 2010-03-25
JP5902123B2 (ja) 2016-04-13
PL2340029T3 (pl) 2014-12-31
PT2340029E (pt) 2014-05-13
WO2010030359A2 (en) 2010-03-18
EP2340029B1 (en) 2014-03-05
ES2475163T3 (es) 2014-07-10
EP2468285A1 (en) 2012-06-27
DK2805726T3 (en) 2018-07-30
NZ605550A (en) 2014-06-27
PL2468286T3 (pl) 2014-09-30
CY1120780T1 (el) 2019-12-11
PL2468285T3 (pl) 2015-03-31
JP5534533B2 (ja) 2014-07-02
LT2805726T (lt) 2018-08-10
KR101487726B1 (ko) 2015-01-29
CL2012001495A1 (es) 2013-07-12
CA2736895C (en) 2016-02-09
WO2010030359A8 (en) 2011-05-12
DK2468286T3 (da) 2014-07-28
KR101379365B1 (ko) 2014-03-31
MX2011002486A (es) 2011-04-26
EP2468287A1 (en) 2012-06-27
LU92667I2 (fr) 2015-11-24
HRP20140493T1 (hr) 2014-07-18
HK1170937A1 (zh) 2013-03-15
PL2468287T3 (pl) 2014-09-30
HRP20140492T1 (hr) 2014-09-12
PE20110704A1 (es) 2011-11-12
IL218441A (en) 2015-09-24
JP2013163680A (ja) 2013-08-22
EP2805726A1 (en) 2014-11-26
TR201809771T4 (tr) 2018-07-23
TW201231064A (en) 2012-08-01
KR20100031092A (ko) 2010-03-19
NO2015014I2 (no) 2015-04-22
CN101775017A (zh) 2010-07-14
CL2011000512A1 (es) 2011-06-17
AU2009292182B2 (en) 2013-06-06
BRPI0918724B8 (pt) 2021-05-25
AR086181A2 (es) 2013-11-27
CY1115844T1 (el) 2017-01-25
PT2468286E (pt) 2014-07-15
JP5259537B2 (ja) 2013-08-07
CY1115137T1 (el) 2016-04-13
CN101775017B (zh) 2014-04-30
EP2340029A2 (en) 2011-07-06
JP2013227314A (ja) 2013-11-07
PE20140961A1 (es) 2014-08-24
US20140148573A1 (en) 2014-05-29
NZ592170A (en) 2013-02-22
ES2677644T3 (es) 2018-08-06
JP5801342B2 (ja) 2015-10-28
BRPI0918724A2 (pt) 2013-06-18
CY2015014I1 (el) 2016-08-31
TWI429449B (zh) 2014-03-11
EP2468287B1 (en) 2014-04-23
US20120196792A1 (en) 2012-08-02
TWI510245B (zh) 2015-12-01
PT2468285E (pt) 2015-02-04
UY33981A (es) 2013-10-31
TW201417826A (zh) 2014-05-16
CY2015014I2 (el) 2016-08-31
CN103896950A (zh) 2014-07-02
DOP2011000077A (es) 2011-04-30
GT201100056BA (es) 2015-04-22
IL234969A0 (en) 2014-11-30
DK2468285T3 (en) 2015-01-19
SI2468286T1 (sl) 2014-08-29
EP2340029A4 (en) 2012-06-13
EP2468286A1 (en) 2012-06-27
SI2805726T1 (sl) 2018-09-28
SI2468287T1 (sl) 2014-08-29
CY1115379T1 (el) 2017-01-04
KR20120044316A (ko) 2012-05-07
EP2468286B1 (en) 2014-04-23
KR20140056195A (ko) 2014-05-09
TW201023875A (en) 2010-07-01
NO2015014I1 (no) 2015-05-04
MY159820A (en) 2017-02-15
LTC2340029I2 (lt) 2016-12-27
PL2805726T3 (pl) 2018-11-30
DK2468287T3 (da) 2014-07-28
PA8842201A1 (es) 2010-04-21
JP2012136546A (ja) 2012-07-19
NL300730I2 (ja) 2016-01-07
EP2468285B1 (en) 2014-10-15
UY32099A (es) 2010-04-30
HUE039478T2 (hu) 2019-01-28
WO2010030359A3 (en) 2010-05-27
CY1115202T1 (el) 2017-04-26
EP2805726B1 (en) 2018-05-02
PT2468287E (pt) 2014-07-15
CO6341565A2 (es) 2011-11-21
ES2459390T3 (es) 2014-05-09
HRP20181075T1 (hr) 2018-09-07
PE20121312A1 (es) 2012-10-28
US8642538B2 (en) 2014-02-04
BR122012005261A8 (pt) 2017-09-19
SI2468285T1 (sl) 2015-01-30
DK2340029T3 (da) 2014-06-10
EA201170434A1 (ru) 2011-10-31
ZA201200950B (en) 2013-09-25
US8420596B2 (en) 2013-04-16
PT2805726T (pt) 2018-07-23
SI2340029T1 (sl) 2014-08-29
EA022891B1 (ru) 2016-03-31
UY35259A (es) 2015-08-31
HK1159515A1 (en) 2012-08-03

Similar Documents

Publication Publication Date Title
HUS1500020I1 (hu) Makrociklusos Hepatitis C szerin proteáz inhibitorok
EP2224801A4 (en) MACROCYCLIC INHIBITORS OF THE OXIMYL TYPE OF HEPATITIS C VIRUS SERINE PROTEASE
HK1144198A1 (en) Macrocyclic serine protease inhibitors
EP2219454A4 (en) HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE
IL195515A0 (en) Macrocyclic oximyl hepatitis c protease inhibitors
HK1223955A1 (zh) 大環脯氨酸衍生的 絲氨酸蛋白酶抑制劑
EP2224920A4 (en) PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
EP2576564A4 (en) MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
EP2658859A4 (en) MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
ZA200810235B (en) Macrocyclic oximyl hepatitis C protease inhibitors
TH0901004135A (th) สารยับยั้งเซอรีนโปรตีเอสของตับอักเสบซีชนิดแมโครไซคลิก

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200905